GSK's Nucala For COPD Needs Better-Defined Patient Population, US FDA Panel Says
Unclear data on monoclonal antibody's efficacy caused many members of Pulmonary-Allergy Drugs Advisory Committee to vote against recommending approval.
You may also be interested in...
Mepolizumab would be first drug for chronic obstructive pulmonary disorder to use eosinophil count as a biomarker, but FDA’s complete response letter says more clinical data are needed.
AstraZeneca has failed to show that its LAMA/LABA combo Bevespi Aerosphere is better than GSK’s Anoro Ellipta in a Phase IIIb study, a result “inconsistent” with previous data, but not surprising according to experts.
US FDA was hoping Pulmonary-Allergy Drugs Advisory Committee could help provide some clarity on its use, but there still are many questions.